What this means in practice
dMMR endometrial cancer
Durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, must be funded in the NHS in England for untreated primary advanced or recurrent endometrial cancer that is dMMR in adults who can have systemic treatment, if it is considered the most suitable treatment option. It should be stopped after 3 years, or earlier if there is disease progression or unacceptable toxicity.
Early funding for durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, is available through the Cancer Drugs Fund from the point of marketing authorisation or release of positive draft guidance, whichever is later. Funding is available until 90 days after final publication of this guidance. After that, durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, must be funded through routine commissioning in England.
There is enough evidence to show that durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy provides benefits and value for money in adults whose cancer is dMMR, so it can be used routinely across the NHS in this population.
pMMR endometrial cancer
Durvalumab with platinum-based chemotherapy, then maintenance durvalumab plus olaparib, is not required to be funded in the NHS in England for untreated primary advanced or recurrent endometrial cancer that is pMMR in adults who can have systemic treatment. It should not be used routinely in the NHS in England in this population.
This is because the available evidence does not suggest that durvalumab with platinum-based chemotherapy, then maintenance durvalumab plus olaparib, offers value for money in adults whose endometrial cancer is pMMR.
NICE has produced tools and resources to support the implementation of this guidance.